Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma

Ishtiaque Ahmad, Zabih Ullah¹, Mohd Ibrahim Khan², Abdullah Khaloofa Alahmari³, Mohd. Faiyaz Khan³

Scientific Research Center, Prince Sultan Military Medical City, ¹Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, ²Department of Pharmaceutical Sciences, College of Pharmacy and Dentistry, Buraydah Colleges, Alqassim, Saudi Arabia, ³Department of Pharmaceutical Sciences SIHAS, Sam Higginbottom, University of Agriculture Technology and Sciences, Naini, Prayagraj, India

J. Adv. Pharm. Technol. Res.

INTRODUCTION

Fluoxetine (FLX) is mainly administered for the management of major depressive disorder (MDD). MDD is characterized by mood depression, losing interest in daily activities, altered cognitive functions, and deteriorating physical health, and these symptoms altogether result in a low quality of life.¹ The pharmacotherapy of MDD utilizes FLX and aims to elevate the mood without causing significant side effects and to prevent the relapse of the diseases.² Chemically, FLX “(R,S)-N-methyl-3-phenyl-3-[4-(trifluoromethyl) phenoxy] propan-1-amine” is containing both R and S racemates [Figure 1] and categorized as an inhibitor of selective serotonin reuptake (SSRI).³ SSRIs are considered safer than other antidepressant drugs due

Access this article online

Quick Response Code:
Website: www.japtr.org
DOI: 10.4103/japtr.JAPTR_308_20

How to cite this article: Ahmad I, Ullah Z, Khan MI, Alahmar AK, Khan MF. Development and validation of an automated solid-phase extraction-LC-MS/MS method for the bioanalysis of fluoxetine in human plasma. J Adv Pharm Technol Res 2021;12:267-73.

Key words: Automation, fluoxetine, human plasma, mass spectrometry, solid-phase extraction

Address for correspondence:
Dr. Mohd Faiyaz Khan,
Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Riyadh, Saudi Arabia.
E-mail: moh.khan@psau.edu.sa, drfaiyaz@live.com

Submitted: 10-Dec-2020 Revised: 16-Feb-2021 Accepted: 10-Mar-2021 Published: 16-Jul-2021

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

© 2021 Journal of Advanced Pharmaceutical Technology & Research | Published by Wolters Kluwer - Medknow

© 2021 Journal of Advanced Pharmaceutical Technology & Research | Published by Wolters Kluwer - Medknow

© 2021 Journal of Advanced Pharmaceutical Technology & Research | Published by Wolters Kluwer - Medknow

© 2021 Journal of Advanced Pharmaceutical Technology & Research | Published by Wolters Kluwer - Medknow
Ahmad, et al.: Automated SPE-LCMS method to quantify fluoxetine in human plasma

to mild adverse effects, hence approved for pregnancy, teenagers, and children populations. FLX is metabolized by N-demethylation into active metabolite norfluoxetine in the liver. However, active metabolites’ production takes a few days due to the longer half-life of the parent compound. Thus, it becomes challenging to measure the active metabolite in the plasma. It requires conducting studies with a longer duration, which adds to limitations as these studies involving human volunteers. As a result, most of the analytical studies rely on the measurement of FLX levels in biological fluids for pharmacokinetic and pharmacodynamic extrapolations.

Several methods are available for the quantification of FLX, including the high-pressure liquid chromatographic (HPLC) methods with fluorescence detection, electrochemical detection, and gas chromatography, and HPLC along with MS detection. However, all the methods involve manual extraction of the compound of interest from the biological samples and subsequent chromatographic separation and quantification. The sample preparation process in the chromatographic analysis is considered a very crucial step. When it is manual, it makes the process very tiresome and time-consuming and leads to compromised final results with reduced precision and accuracy. In addition to compromised results, due to manual extraction, these methods have long run time, low sensitivity, narrow range, and require a large volume of biological samples. As per the available literature up to now, no methods are available for the quantification of FLX with this broad range and with automatic extraction process using the RapidTrace® (Biotage) solid-phase extraction (SPE) unit.

Here, we established a simple, fast, responsive, and robust tandem LC-MS/MS technique for the quantitative assessment of FLX in human K3EDTA plasma. An automated SPE system was used to increase the process accuracy and precision. Plasma concentrations of FLX were analyzed by using the +ve ion electrospray ionization with the multiple-reaction monitoring (MRM) technique. The approach was validated following the USFDA Bioanalytical Method Validation Guideline.

MATERIALS AND METHODS

Working standards and chemicals
The reference working standards of FLX (98.71%) and FLX-d5 (99.9%) were procured from Clearsynth Ltd., India. Acetonitrile and methanol, liquid ammonia (25% NH₃), orthophosphoric acid, and ammonium formate were procured from Sigma-Aldrich, Germany. In-house preparation used Milli-Q water (Direct-Q WPS) in the study.

Instrument and conditions
Chromatographic/mass spectrometric condition
Shimadzu HPLC was used to perform chromatographic separation on an Ascentis® Express C18 reverse-phase column, which includes a pump (LC-10ADVR), column oven (CTO-10AVP), and an autosampler (SIL-HTC). The column oven was integrated with an autosampler; 10 µL of extracted samples was directed to the column at 10°C. Mobile phase, acetonitrile (CAN) as well as 5.0 mM ammonium formate in a ratio of 90:10 (v/v) were included in isocratic mode, with a flow rate of 0.5 mL/min. Ions were identified in the +ve MRM mode by monitoring the m/z transition at 310.0/44.1 for FLX and 315.0/44.0 for the internal standard (IS) in unit-unit resolution. Analyst Software Version 1.4.2 (ABS Sciex, Framingham, MA0170, USA) was used to analyze and process the data.

Standard solution preparation
The stock solutions of FLX and FLX-d5 were prepared in ACN and Milli-Q water (70:30 v/v) at 1 mg/ml. All the stock dilutions were prepared in diluent, water, and methanol (50:50 v/v) under the low-light condition and stored in refrigerator. The calibration curve and quality controls (QCs) were obtained by diluting a sufficient stock solution to obtain plasma concentration between 0.201 and 30.00 ng/ml and for IS as 50 ng/mL in the diluent.

Sample preparation/extraction
The automated SPE technique was opted to process the plasma samples using RapidTrace® (Biotage) SPE system. The drug extraction from plasma samples was achieved.
through MCX cartridges (30 mg/cc). The extracted samples were evaporated to complete dryness at 45°C ± 2°C using a nitrogen evaporator (RapidVap Vertex evaporator). The dried extracts were reconstituted with mobile phase (500 µL) and transfer into vials for further examination [Table 1].

**Method validation**

USFDA guideline for analytical method validation was chosen to validate the method to test the selectiveness, linearity, precision, accuracy, matrix impact, and drug recovery.[13] In addition to this, other validation parameters tested were analyte and IS stability, benchtop stability, benchtop stability during extraction, freeze-thaw stabilities, long-term stabilities, and standard stock solutions and reference solution stabilities.[13] The reproducibility of the method was evaluated by determining reinjection reproducibility, dilution integrity, and ruggedness.

**RESULTS AND DISCUSSION**

For measuring the concentration of FLX in biological

---

**Table 1: Extraction procedure (RapidTrace™)**

| Steps         | Sources    | Destination          | Volumes (mL) | Flow rate (ml/min) |
|---------------|------------|----------------------|--------------|--------------------|
| Conditioning  | Methanol   | Organic waste        | 1            | 15                 |
| Conditioning  | Water      | Aqueous waste        | 1            | 15                 |
| Loading       | Sample     | Biowaste             | 0.65         | 1                  |
| Purge cannula | Water      | Cannula waste        | 2            | 30                 |
| Rinsing       | Washing solution | Biowaste      | 1            | 2                  |
| Rinsing       | Washing solution | Biowaste      | 1            | 2                  |
| Rinsing       | Methanol   | Biowaste             | 1            | 2                  |
| Rinsing       | Methanol   | Biowaste             | 1            | 2                  |
| Drying        | Time (5 min) |                    |              |                    |
| Collection    | Elution solution | Fraction-1   | 1            | 30                 |
| Collection    | Elution solution | Fraction-1   | 1            | 30                 |
| Purge cannula | Methanol   | Cannula waste        | 2            | 30                 |
| Purge cannula | Water      | Cannula waste        | 2            | 30                 |

**Table 2: Summary of chromatographic and mass spectrometric conditions**

| Parameter                  | Optimized Condition                                      |
|----------------------------|----------------------------------------------------------|
| Column name                | Ascentis Express C18 column (75 mm×4.6 mm×2.7 µm)       |
| Mobile phase               | Acetonitrile: 5.0 mM ammonium formate (90:10 v/v)        |
| Oven temperature           | 40                                                       |
| Injected volume (µl)       | 10                                                      |
| Flow rate (mL/min)         | 0.5                                                     |
| Detector                   | MS/MS                                                   |
| Gas-1 (nebulizer)          | 50                                                      |
| Gas-2 (heater gas)         | 50                                                      |
| Curtain gas                | 18                                                      |
| Collision gas              | 6                                                       |
| Ion source                 | Turbo-ion spray (positive ion mode)                      |
| Temperature                | 450                                                     |
| IS voltage                 | 4500 V                                                  |
| DE clustering potential    | 18                                                      |
| Entrance potential         | 10                                                      |
| Collision energy           | 10                                                      |
| collision cells exit potential | 9                                          |
| Dwell time (ms)            | 200                                                     |
| M/z ion fluoxetine         | 310.0/44.1                                              |
| M/z fluoxetine-d5          | 315.0/44.0                                              |
| Sample cooler temperature  | 10±2                                                    |
| Rinsing solution           | Methanol: Water (50:50 v/v)                             |
| Retention time (fluoxetine), min | 1.5-1.8                                           |
| Right (fluoxetine d5), min | 1.5-1.8                                                 |
| Run time (min)             | 3.5                                                     |

IS: Internal standard, MS: Mass Spectrometry
matrices, few HPLC, gas chromatography mass spectrometry (GCMS) and liquid chromatography mass spectrometry (LCMS) methods are available.\[10,14,15\] These methods, however, have some drawbacks, therefore, LC-MS/MS approach for measuring FLX was considered by utilizing the RapidTrace® automated SPE system,\[16,17\] and detailed processes are given in Table 1. To create a reliable, consistent, and reproducible LC-MS/MS method chromatographic, separation conditions were optimized after MS/MS optimization to offer adequate separation and peak symmetry with an appropriate response.\[18,19\] Chromatographic and mass spectrometric conditions are established in Table 2.

The method was developed and validated keeping in mind a bioequivalence pharmacokinetic approach, in which healthy subjects were involved. The evaluation of parameters such as selectiveness, linearity, precisions and accuracies, drug recovery, stabilities (freeze-thaw, benchtop, long-term, and stock solution stabilities), and ruggedness was completed for the validation of the method.\[20,21\] The selectivity was performed on different lots of hemolyzed and lipemic plasma samples. Insignificant interference was found in the various plasma sets tested at the RT of FLX and FLX-d5 [Table 3]. A graph of a representation of regression calibration curve is provided in Figure 2.

The coefficient of variation (CV) of the experiment was calculated by using QC as a % mark scale of sample concentration. Table 4 shows the precision and accuracy statistics for the interday and intraday periods. The chromatograms of FLX and FLX-d5 blank samples, blank + IS samples, limit of quantitation (LOQ) and upper limit of quantitation (ULOQ) are presented in Figures 3-6, respectively.
The presence matrix effect will alter the ionization pattern of analytes present in the matrix. Thus, the technique was designed to evade any effect on the matrix. It was found that the absolute matrix effect was 98.4%, 98.5%, and 99.5% at lower, middle, and higher levels, respectively. This indicated that matrix effect in the presence of plasma was found to be negligible. The mean overall recovery of FLX was found to be 68.63%, with a precision of 13.58%.

Whereas, the mean overall recovery of FLX-d5 was found to be 61.2%, with a precision of 4.7%. Table 5 shows the comparative recoveries and complete matrix effects with procedure proficiencies for FLX and FLX-d5.

The stability was performed in both matrices, namely aqueous as well as plasma, and the results of the stability exercise are tabulated in Table 6. It is evident and apparent

Table 3: Blank screening and selectivity

| Blank ID | Interference fluoxetine | LOQ area-fluoxetine (%) | Interference fluoxetine-d5 | IS area (%) |
|----------|--------------------------|-------------------------|-----------------------------|-------------|
| B-01     | 83                       | 16,283 (0.50)           | 80                          | 1,462,938 (0.005) |
| B-02     | 62                       | 17,995 (0.30)           | 90                          | 1,398,671 (0.006) |
| B-03     | 2                        | 15,388 (0.00)           | 63                          | 1,351,752 (0.005) |
| B-04     | 31                       | 14,124 (0.20)           | 23                          | 1,230,928 (0.002) |
| B-05     | 20                       | 14,850 (0.10)           | 50                          | 1,434,412 (0.003) |
| B-06     | 109                      | 14,036 (0.80)           | 211                         | 1,132,306 (0.019) |
| B-07     | 12                       | -                       | 300                         |             |
| B-08     | 6                        | -                       | 230                         |             |
| B-09     | 78                       | -                       | 150                         |             |
| B-10     | 45                       | -                       | 186                         |             |
| Mean     |                          | 15,446                  | 1,335,168                   |             |
| SD       |                          | 1502.820                | 128,453                     |             |
| Percentage CV |                          | 9.730                   | 9.6                         |             |

IS: Internal standard, SD: Standard deviation, LOQ: Limit of quantitation, CV: Coefficient of variation

Table 4: Intraday and interday precision and accuracy of fluoxetine

| Nominal concentration (ng/mL) | Intraday (n=6) | Inter day (n=18) |
|------------------------------|---------------|------------------|
|                              | Intraday       | Interday         |
|                              | Mean concentration±SD | Precision (%) | Accuracy (%) | Mean concentration±SD | Precision (%) | Accuracy (%) |
| 0.203 (LOQQC)                | 0.203±0.01     | 7.26             | 99.92         | 0.192±0.01       | 7.7          | 94.69        |
| 0.583 (LQC)                  | 0.603±0.01     | 1.92             | 108.06        | 0.629±0.02       | 2.57         | 107.8        |
| 12.677 (MQC)                 | 12.405±0.32    | 2.58             | 97.93         | 12.543±0.38      | 3.02         | 99.02        |
| 25.353 (HQC)                 | 25.218±0.51    | 2.02             | 99.47         | 25.018±0.61      | 2.42         | 98.68        |

SD: Standard deviation, LOQQC: Lowest limit of quantification quality control, LQC: Low quality control, MQC: Medium quality control, HQC: High quality control

The presence matrix effect will alter the ionization pattern of analytes present in the matrix. Thus, the technique was designed to evade any effect on the matrix. It was found that the absolute matrix effect was 98.4%, 98.5%, and 99.5% at lower, middle, and higher levels, respectively. This indicated that matrix effect in the presence of plasma was found to be negligible. The mean overall recovery of FLX was found to be 68.63%, with a precision of 13.58%.

Whereas, the mean overall recovery of FLX-d5 was found to be 61.2%, with a precision of 4.7%. Table 5 shows the comparative recoveries and complete matrix effects with procedure proficiencies for FLX and FLX-d5.

The stability was performed in both matrices, namely aqueous as well as plasma, and the results of the stability exercise are tabulated in Table 6. It is evident and apparent
Ahmad, et al.: Automated SPE-LCMS method to quantify fluoxetine in human plasma

**Figure 6**: Representative multiple reaction monitoring chromatograms of upper level of quantification samples in plasma: fluoxetine (left) and fluoxetine-d5 (right)

**Table 5: Matrix effect and recovery for fluoxetine and fluoxetine-d5**

| QC | A (CV %) | B (CV %) | C (CV %) | Absolute ME (%) | RE (%) |
|----|----------|----------|----------|-----------------|-------|
| LQC | 45142.20 (4.6) | 44423.70 (8.66) | 35268.20 (6.51) | 98.41 | 79.39 |
| MQC | 974522.10 (4.64) | 960072.67 (2.48) | 609186.83 (6.52) | 98.52 | 63.45 |
| HQC | 1915432.40 (2.99) | 1905052.00 (2.90) | 1200998.20 (4.10) | 99.46 | 63.04 |
| ISD | 1234584.60 (7.39) | 1229850.70 (0.70) | 753278.20 (4.25) | 99.62 | 61.25 |

QC: Quality control, ME: Matrix effect, LQC: Low quality control, MQC: Medium quality control, HQC: High quality control, RE: Relative recovery, ISD: Internal standard dilution, CV: Coefficient of variation

**Table 6: Stability data for fluoxetine and fluoxetine-d5**

| Storage condition | QC (ng/mL) | Precision (%) | Accuracy (%) | Stability (%) |
|-------------------|------------|---------------|-------------|---------------|
| Benchtop stability (14.50 h) | LQC | 4.35 | 96.10 | 101.44 |
| | HQC | 2.52 | 100.71 | 98.14 |
| Benchtop extraction stability (14.53 h) | LQC | 2.38 | 98.54 | 98.37 |
| | HQC | 1.94 | 102.96 | 102.52 |
| Long-term stability (15 days) | LQC | 3.93 | 95.31 | 96.52 |
| | HQC | 1.34 | 102.50 | 98.97 |
| Freeze-thaw stability (3 cycles) | LQC | 2.81 | 102.8 | 95.45 |
| | HQC | 2.70 | 99.30 | 101.27 |
| In-injector stability (52.50 h) | LQC | 5.29 | 94.16 | 96.35 |
| | HQC | 2.74 | 95.21 | 93.05 |
| Reinjection reproducibility (52.50 h) | LQC | 1.21 | 91.00 | 98.61 |
| | HQC | 0.82 | 98.27 | 101.46 |

QC: Quality control, LQC: Low quality control, HQC: High quality control

**Table 7: Precision and accuracy batch for the ruggedness**

| Nominal concentration (ng/mL) | Mean±SD | Precision (%) | Accuracy (%) |
|------------------------------|---------|---------------|--------------|
| 0.203 (LOQQC) | 0.192±0.01 | 2.82 | 94.33 |
| 0.583 (LQC) | 0.615±0.02 | 3.95 | 105.55 |
| 12.677 (MQC) | 12.847±0.12 | 0.93 | 101.34 |
| 25.353 (HQC) | 25.480±0.04 | 0.16 | 100.51 |

SD: Standard deviation, LOQQC: Lowest limit of quantification quality control, LQC: Low quality control, MQC: Medium quality control, HQC: High quality control
that analytes as well as IS stability samples were found to be stable under different storage circumstances. The QC samples were prepared to determine dilution accuracy. The nominal percentage of dilution integrity was found to be 94.9% and 94.2% after 2–4 times dilution, whereas the percentage of CV was stated to be 2.9 and 6.8%, respectively. The method showed ruggedness for the selected validation range [Table 7].

CONCLUSION

In this method, a reverse-phase chromatographic method with tandem mass spectrometric detection using FLX-d5 as an IS was developed in the K3EDTA plasma. Chromatographic separation with a lower baseline was achieved using mobile phase with acetonitrile and ammonium formate buffer. The maximum response was observed using the reverse-phase Ascentis® Express C18 column at an optimized flow rate (0.5 ml/min). This technique was established and found to be rapid, specific, precise, and linear and can facilitate the biostudies of FLX. Chromatographic and extraction parameters have been designed to achieve a short-run time and a fast, automated plasma sample processing procedure due to the chromatographic run duration of 3.5 min and retention time of 1.6 min. Thus, the method makes a high sample throughput. This approach can also be implemented in a clinical laboratory for therapeutic drug control, enabling individual dosage optimization, drug interaction identification, and patient compliance evaluation.

Acknowledgment

The publication was supported by Deanship of Scientific Research at Prince Sattam bin Abdulaziz University and the authors extend their appreciation to Prince Sultan Military Medical City for providing technical support.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Visentin AP, Colombo R, Scotta E, Fracasso DS, da Rosa AR, Branco CS, et al. Targeting inflammatory-mitochondrial response in major depression: Current evidence and further challenges. Oxid Med Cell Longev 2020;2020:2972968.

2. Severe J, Greden JF, Reddy P. Consequences of recurrence of major depressive disorder: Is stopping effective antidepressant medications ever safe? Focus (Am Psychiatr Publ) 2020;18:120-8.

3. Latha MS, Sowjanyab A, Abbulu K. Analytical method development for the simultaneous estimation of olanzapine and fluoxetine by RP-HPLC method. Int J Bio Pharm Res 2019;8:2769-74.

4. Creeley CE, Denton LK. Use of prescribed psychotropics during pregnancy: A systematic review of pregnancy, neonatal, and childhood outcomes. Brain Sci 2019;9:235.

5. Marazzi D, Avella MT, Basile L, Mucci F, Dell’Osso L. Pharmacokinetics of serotonergic drugs: Focus on OCD. Expert Opin Drug Metab Toxicol 2019;15:261-73.

6. Al-Shalabi R, Hefnawy M, Al-Johar H, Alrabiah H. Validated UPLC-MS/MS method for the simultaneous quantification of vortioxetine and fluoxetine in plasma: Application to their pharmacokinetic interaction study in wistar rats. Am J Anal Chem 2020;11:233-59.

7. Higashi Y, Gao R, Fujiy Y. Determination of fluoxetine and norfluoxetine in human serum and urine by HPLC using a cholester column with fluorescence detection. J Liq Chrom Relat Tech 2009;32:1141-51.

8. Urichuk LJ, Aspeslet LJ, Holt A, Silverstone PH, Cousts RT, Baker GB. Determination of p-trifluoromethylphenol, a metabolite of fluoxetine, in tissues and body fluids using an electron-capture gas chromatographic procedure. J Chromatogr B Biomed Sci Appl 1997;698:103-9.

9. Oliveira AF, de Figueiredo EC, dos Santos-Neto AJ. Analysis of fluoxetine and norfluoxetine in human plasma by liquid-phase microextraction and injection port derivatization GC-MS. J Pharm Biomed Anal 2013;73:53-8.

10. Bonde SL, Bhadane RP, Gaikwad A, Gavali SR, Katakale DU, Narendiran AS. Simultaneous determination of olanzapine and fluoxetine in human plasma by LC-MS/MS: Its pharmacokinetic application. J Pharm Biomed Anal 2014;90:64-71.

11. Tiwari G, Tiwari R. Bioanalytical method validation: An updated review. Pharm Methods 2010;1:25-38.

12. Tanathitiphuwarat N, Tanudechpong P, Chariyavilaskul P, Prompila N, Tansrisawad N, Tubitimrattana A, et al. Development and validation of an ultra-performance liquid chromatography mass spectrometry/mass spectrometry method for simultaneous quantification of total and free mycophenolic acid and its metabolites in human plasma. J Adv Pharm Technol Res 2020;11:207-12.

13. Alvi SN, Hammami MM. An improved method for measurement of testosterone in human plasma and saliva by ultra-performance liquid chromatography-tandem mass spectrometry. J Adv Pharm Technol Res 2020;11:64-8.

14. Reddy BV, Reddy KS, Sreeramu J, Kanumula G. Simultaneous determination of olanzapine and fluoxetine by HPLC. Chromatographia 2007;66:111-4.

15. Mifsud J, Sghendo LJ. A novel chiral GC/MS method for the analysis of fluoxetine and norfluoxetine enantiomers in biological fluids. J Pharm Bioallied Sci 2012;4:236-45.

16. Wells DA. Sample preparation for mass spectrometry applications. In: Principles and Applications of Clinical Mass Spectrometry. Amsterdam: Elsevier; 2018. p. 67-91.

17. Vuckovic D, Cudjoe E, Hein D, Pawliszyn J. Automation of solid-phase microextraction in high-throughput format and applications to drug analysis. Anal Chem 2008;80:6870-80.

18. Beccaria M, Cabooter D. Current developments in LC-MS for pharmaceutical analysis. Analyst 2020;145:1129-57.

19. Bajad SU, Lu W, Kimball EH, Yuan J, Peterson C, Rabinowitz JD. Separation and quantitation of water soluble cellular metabolites by hydrophilic interaction chromatography-tandem mass spectrometry. J Chromatogr A 2006;1125:76-88.

20. Food and Drug administration (FDA). Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2018.

21. Use CIMP, EMA. Guideline on Bioanalytical Method Validation. London, UK: Use CIMP, EMA; 2011.